Putzki Norman, Maschke Matthias, Drepper Johannes, Diener Hans-Chr, Timmann Dagmar
Department of Neurology, University of Essen, Hufelandstrasse 55, Germany.
J Neurol. 2002 Jul;249(7):824-8. doi: 10.1007/s00415-002-0727-z.
Animal studies have demonstrated potent antiparkinsonian and other motor effects of the functional NMDA-antagonist flupirtine and suggest a therapeutic use in Parkinson's disease (PD). In healthy subjects flupirtine decreases the functionally destabilizing medium latency (ML) response following toe-up rotations of a moving platform. Because ML responses are known to be increased in PD, this study examined s the effects of flupirtine on postural responses in patients with PD. During 22 days 21 patients with PD took 50 mg, 100 mg flupirtine or placebo following a randomized, double-blind design. Clinical impairment was assessed by means of the Unified Parkinson's Disease Rating Scale (UPDRS). No significant difference between the effect of flupirtine and placebo on ML responses was observed. There was an unspecific improvement of overall UPDRS scores in placebo and flupirtine conditions compared with baseline measures which was more marked in the placebo condition. No improvement in the UPDRS motor subscale was observed. As no beneficial effect on the clinical presentation and no effect on postural responses could be demonstrated, flupirtine does not seem to be a therapeutic option in PD.
动物研究已证实功能性N-甲基-D-天冬氨酸（NMDA）拮抗剂氟吡汀具有显著的抗帕金森病及其他运动效应，并提示其在帕金森病（PD）治疗中的应用潜力。在健康受试者中，氟吡汀可降低移动平台向上旋转时功能上不稳定的中潜伏期（ML）反应。由于已知PD患者的ML反应会增强，本研究考察了氟吡汀对PD患者姿势反应的影响。在22天内，21例PD患者按照随机、双盲设计服用50毫克、100毫克氟吡汀或安慰剂。通过统一帕金森病评定量表（UPDRS）评估临床损伤情况。未观察到氟吡汀和安慰剂对ML反应的影响存在显著差异。与基线测量相比，安慰剂组和氟吡汀组的UPDRS总分均有非特异性改善，且在安慰剂组更为明显。UPDRS运动子量表未见改善。由于未证明氟吡汀对临床表现有有益作用，也未观察到对姿势反应的影响，因此氟吡汀似乎不是PD的治疗选择。
